Special Considerations in the Management of Women with Epilepsy in Reproductive Years
Abstract
:1. Introduction
2. Seizures and Reproductive Health
3. Anti-Seizure Medications and Reproductive Health
4. Appropriate Anti-Seizure Medications during the Reproductive Age
5. Anti-Seizure Medications and Hormonal Contraceptives
6. Appropriate Contraception during Reproductive Age
7. Special Considerations for Catamenial Epilepsy
8. Specialized Considerations for Pregnancy
9. Discussion
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Herzog, A.G.; Klein, P.; Rand, B.J. Three Patterns of Catamenial Epilepsy. Epilepsia 1997, 38, 1082–1088. [Google Scholar] [CrossRef] [PubMed]
- Morrell, M.J.; Montouris, G.D. Reproductive Disturbances in Patients with Epilepsy. Clevel. Clin. J. Med. 2004, 71, S19. [Google Scholar] [CrossRef]
- Anderson, G.D. Pregnancy-Induced Changes in Pharmacokinetics. Clin. Pharmacokinet. 2005, 44, 989–1008. [Google Scholar] [CrossRef]
- Voinescu, P.E.; Park, S.; Chen, L.Q.; Stowe, Z.N.; Newport, D.J.; Ritchie, J.C.; Pennell, P.B. Antiepileptic Drug Clearances during Pregnancy and Clinical Implications for Women with Epilepsy. Neurology 2018, 91, e1228–e1236. [Google Scholar] [CrossRef]
- Berlin, M.; Barchel, D.; Gandelman-Marton, R.; Brandriss, N.; Blatt, I.; Ziv-Baran, T.; Neufeld, M.Y.; Dinavitser, N.; Kohn, E.; Shaniv, D.; et al. Therapeutic Levetiracetam Monitoring during Pregnancy: “Mind the Gap”. Ther. Adv. Chronic. Dis. 2019, 10, 2040622319851652. [Google Scholar] [CrossRef] [Green Version]
- Spiegel, R.; Merius, H. Principles of Epilepsy Management for Women in Their Reproductive Years. Front. Neurol. 2020, 11. [Google Scholar] [CrossRef]
- Tomson, T.; Xue, H.; Battino, D. Major Congenital Malformations in Children of Women with Epilepsy. Seizure 2015, 28, 46–50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Morrow, J. Malformation Risks of Antiepileptic Drugs in Pregnancy: A Prospective Study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatry 2006, 77, 193–198. [Google Scholar] [CrossRef]
- Cavalli, P. Prevention of Neural Tube Defects and Proper Folate Periconceptional Supplementation. J. Prenat. Med. 2008, 2, 40–41. [Google Scholar]
- Vajda, F.J.E.; O’Brien, T.J.; Graham, J.E.; Hitchcock, A.A.; Perucca, P.; Lander, C.M.; Eadie, M.J. Folic Acid Dose, Valproate, and Fetal Malformations. Epilepsy Behav. 2021, 114, 107569. [Google Scholar] [CrossRef] [PubMed]
- Drislane, F.W.; Coleman, A.E.; Schomer, D.L.; Ives, J.; Levesque, L.A.; Seibel, M.M.; Herzog, A.G. Altered Pulsatile Secretion of Luteinizing Hormone in Women with Epilepsy. Neurology 1994, 44, 306. [Google Scholar] [CrossRef]
- Bilo, L.; Meo, R.; Valentino, R.; Buscaino, G.A.; Striano, S.; Nappi, C. Abnormal Pattern of Luteinizing Hormone Pulsatility in Women with Epilepsy. Fertil. Steril. 1991, 55, 705–711. [Google Scholar] [CrossRef]
- Herzog, A.G.; Seibel, M.M.; Schomer, D.L.; Vaitukaitis, J.L.; Geschwind, N. Reproductive Endocrine Disorders in Women With Partial Seizures of Temporal Lobe Origin. Arch. Neurol. 1986, 43, 341–346. [Google Scholar] [CrossRef]
- Herzog, A.G. Disorders of Reproduction in Patients with Epilepsy: Primary Neurological Mechanisms. Seizure 2008, 17, 101–110. [Google Scholar] [CrossRef] [Green Version]
- Svalheim, S.; Taubøll, E.; Bjørnenak, T.; Røste, L.S.; Mørland, T.; Sætre, E.R.; Gjerstad, L. Do Women with Epilepsy Have Increased Frequency of Menstrual Disturbances? Seizure 2003, 12, 529–533. [Google Scholar] [CrossRef] [Green Version]
- Kariuki, J.; Joshi, M.; Adam, A.; Kwasa, T.; Machoki, M. Fertility Rate of Epileptic Women at Kenyatta National Hospital. East Afr. Med. J. 2008, 85, 341–346. [Google Scholar] [CrossRef] [Green Version]
- Olafsson, E.; Hauser, A.W.; Gudmundsson, G. Fertility in Patients with Epilepsy: A Population-Based Study. Neurology 1998, 51, 71–73. [Google Scholar] [CrossRef]
- Artama, M. Birth Rate among Patients with Epilepsy: A Nationwide Population-Based Cohort Study in Finland. Am. J. Epidemiol. 2004, 159, 1057–1063. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Webber, M.P.; Hauser, W.A.; Ottman, R.; Annegesr, J.F. Fertility in Persons with Epilepsy: 1935–1974. Epilepsia 1986, 27, 746–752. [Google Scholar] [CrossRef] [PubMed]
- Pennell, P.B.; French, J.A.; Harden, C.L.; Davis, A.; Bagiella, E.; Andreopoulos, E.; Lau, C.; Llewellyn, N.; Barnard, S.; Allien, S. Fertility and Birth Outcomes in Women With Epilepsy Seeking Pregnancy. JAMA Neurol. 2018, 75, 962. [Google Scholar] [CrossRef] [PubMed]
- Anderson, G.D. Pharmacogenetics and Enzyme Induction/Inhibition Properties of Antiepileptic Drugs. Neurology 2004, 63, S3–S8. [Google Scholar] [CrossRef]
- Beastall, G.H.; Cowan, R.A.; Gray, J.M.B.; Fogelman, I. Hormone Binding Globulins and Anticonvulsant Therapy. Scott. Med. J. 1985, 30, 101–105. [Google Scholar] [CrossRef]
- Reddy, D.S. Clinical Pharmacokinetic Interactions between Antiepileptic Drugs and Hormonal Contraceptives. Expert Rev. Clin. Pharmacol. 2010, 3, 183–192. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Harden, C.L. Polycystic Ovaries and Polycystic Ovary Syndrome in Epilepsy: Evidence for Neurogonadal Disease. Epilepsy Curr. 2005, 5, 142–146. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Isojärvi, J.I.; Laatikainen, T.J.; Knip, M.; Pakarinen, A.J.; Juntunen, K.T.; Myllylä, V.V. Obesity and Endocrine Disorders in Women Taking Valproate for Epilepsy. Ann. Neurol. 1996, 39, 579–584. [Google Scholar] [CrossRef] [PubMed]
- Herzog, A.G.; Schachter, S.C. Valproate and the Polycystic Ovarian Syndrome: Final Thoughts. Epilepsia 2001, 42, 311–315. [Google Scholar] [CrossRef] [PubMed]
- Isojärvi, J.I.T.; Rättyä, J.; Myllylä, V.V.; Knip, M.; Koivunen, R.; Pakarinen, A.J.; Tekay, A.; Tapanainen, J.S. Valproate, Lamotrigine, and Insulin-Mediated Risks in Women with Epilepsy: Valproate, Lamotrigine, and Metabolic Disorders. Ann. Neurol. 1998, 43, 446–451. [Google Scholar] [CrossRef] [PubMed]
- Benson, R.; Pack, A. Epilepsy. Handb. Clin. Neurol. 2020, 172, 155–167. [Google Scholar] [CrossRef]
- Campbell, E.; Kennedy, F.; Russell, A.; Smithson, W.H.; Parsons, L.; Morrison, P.J.; Liggan, B.; Irwin, B.; Delanty, N.; Hunt, S.J.; et al. Malformation Risks of Antiepileptic Drug Monotherapies in Pregnancy: Updated Results from the UK and Ireland Epilepsy and Pregnancy Registers. J. Neurol. Neurosurg. Psychiatry 2014, 85, 1029–1034. [Google Scholar] [CrossRef]
- Tomson, T.; Battino, D.; Bonizzoni, E.; Craig, J.; Lindhout, D.; Perucca, E.; Sabers, A.; Thomas, S.V.; Vajda, F.; EURAP Study Group. Comparative Risk of Major Congenital Malformations with Eight Different Antiepileptic Drugs: A Prospective Cohort Study of the EURAP Registry. Lancet Neurol. 2018, 17, 530–538. [Google Scholar] [CrossRef]
- Tomson, T.; Battino, D.; Bonizzoni, E.; Craig, J.; Lindhout, D.; Perucca, E.; Sabers, A.; Thomas, S.V.; Vajda, F.; for The EURAP Study Group. Declining Malformation Rates with Changed Antiepileptic Drug Prescribing: An Observational Study. Neurology 2019, 93, e831–e840. [Google Scholar] [CrossRef]
- Meador, K.J.; Baker, G.A.; Browning, N.; Cohen, M.J.; Bromley, R.; Clayton-Smith, J.; Kalayjian, L.A.; Kanner, A.; Liporace, J.D.; Pennell, P.B.; et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): A prospective observational study. Lancet Neurol. 2013, 12, 244–252. [Google Scholar] [CrossRef] [Green Version]
- Bromley, R.L.; Mawer, G.E.; Briggs, M.; Cheyne, C.; Clayton-Smith, J.; García-Fiñana, M.; Kneen, R.; Lucas, S.B.; Shallcross, R.; Baker, G.A.; et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J. Neurol. Neurosurg. Psychiatry 2013, 84, 637–643. [Google Scholar] [CrossRef] [Green Version]
- Veiby, G.; Daltveit, A.K.; Schjølberg, S.; Stoltenberg, C.; Øyen, A.-S.; Vollset, S.E.; Engelsen, B.A.; Gilhus, N.E. Exposure to antiepileptic drugs in utero and child development: A prospective population-based study. Epilepsia 2013, 54, 1462–1472. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Werler, M.M.; Ahrens, K.A.; Bosco, J.L.F.; Mitchell, A.A.; Anderka, M.T.; Gilboa, S.M.; Holmes, L.B. Use of Antiepileptic Medications in Pregnancy in Relation to Risks of Birth Defects. Ann. Epidemiol. 2011, 21, 842–850. [Google Scholar] [CrossRef] [Green Version]
- Reimers, A.; Brodtkorb, E.; Sabers, A. Interactions between Hormonal Contraception and Antiepileptic Drugs: Clinical and Mechanistic Considerations. Seizure 2015, 28, 66–70. [Google Scholar] [CrossRef] [Green Version]
- Doose, D.R.; Wang, S.-S.; Padmanabhan, M.; Schwabe, S.; Jacobs, D.; Bialer, M. Effect of Topiramate or Carbamazepine on the Pharmacokinetics of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol in Healthy Obese and Nonobese Female Subjects. Epilepsia 2003, 44, 540–549. [Google Scholar] [CrossRef]
- Christensen, J.; Petrenaite, V.; Atterman, J.; Sidenius, P.; Öhman, I.; Tomson, T.; Sabers, A. Oral Contraceptives Induce Lamotrigine Metabolism: Evidence from a Double-Blind, Placebo-Controlled Trial. Epilepsia 2007, 48, 484–489. [Google Scholar] [CrossRef]
- Sabers, A.; Ohman, I.; Christensen, J.; Tomson, T. Oral Contraceptives Reduce Lamotrigine Plasma Levels. Neurology 2003, 61, 570–571. [Google Scholar] [CrossRef] [PubMed]
- Sabers, A.; Buchholt, J.M.; Uldall, P.; Hansen, E.L. Lamotrigine Plasma Levels Reduced by Oral Contraceptives. Epilepsy Res. 2001, 47, 151–154. [Google Scholar] [CrossRef]
- Sidhu, J.; Job, S.; Singh, S.; Philipson, R. The Pharmacokinetic and Pharmacodynamic Consequences of the Co-Administration of Lamotrigine and a Combined Oral Contraceptive in Healthy Female Subjects. Br. J. Clin. Pharmacol. 2006, 61, 191–199. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Herzog, A.G.; Blum, A.S.; Farina, E.L.; Maestri, X.E.; Newman, J.; Garcia, E.; Krishnamurthy, K.B.; Hoch, D.B.; Replansky, S.; Fowler, K.M.; et al. Valproate and Lamotrigine Level Variation with Menstrual Cycle Phase and Oral Contraceptive Use. Neurology 2009, 72, 911–914. [Google Scholar] [CrossRef] [PubMed]
- Rauchenzauner, M.; Deichmann, S.; Pittschieler, S.; Bergmann, M.; Prieschl, M.; Unterberger, I.; Rösing, B.; Seger, C.; Moser, C.; Wildt, L.; et al. Bidirectional Interaction between Oral Contraception and Lamotrigine in Women with Epilepsy–Role of Progestins. Seizure 2020, 74, 89–92. [Google Scholar] [CrossRef] [PubMed]
- Herzog, A.G.; Mandle, H.B.; Cahill, K.E.; Fowler, K.M.; Hauser, W.A.; Davis, A.R. Contraceptive Practices of Women with Epilepsy: Findings of the Epilepsy Birth Control Registry. Epilepsia 2016, 57, 630–637. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Espinera, A.R.; Gavvala, J.; Bellinski, I.; Kennedy, J.; Macken, M.P.; Narechania, A.; Templer, J.; VanHaerents, S.; Schuele, S.U.; Gerard, E.E. Counseling by Epileptologists Affects Contraceptive Choices of Women with Epilepsy. Epilepsy Behav. 2016, 65, 1–6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Davis, A.R.; Saadatmand, H.J.; Pack, A. Women with Epilepsy Initiating a Progestin IUD: A Prospective Pilot Study of Safety and Acceptability. Epilepsia 2016, 57, 1843–1848. [Google Scholar] [CrossRef]
- Bounds, W.; Guillebaud, J. Observational Series on Women Using the Contraceptive Mirena® Concurrently with Anti-Epileptic and Other Enzyme-Inducing Drugs. BMJ Sex. Reprod. Health 2002, 28, 78–80. [Google Scholar] [CrossRef] [Green Version]
- Schwenkhagen, A.M.; Stodieck, S.R.G. Which Contraception for Women with Epilepsy? Seizure 2008, 17, 145–150. [Google Scholar] [CrossRef] [Green Version]
- Frederiksen, M.C. Depot Medroxyprogesterone Acetate Contraception in Women with Medical Problems. J. Reprod. Med. 1996, 41, 414–418. [Google Scholar]
- Berenson, A.B.; Breitkopf, C.R.; Grady, J.J.; Rickert, V.I.; Thomas, A. Effects of Hormonal Contraception on Bone Mineral Density After 24 Months of Use. Obstet. Gynecol. 2004, 103, 899–906. [Google Scholar] [CrossRef] [PubMed]
- Cromer, B.A.; Blair, J.M.; Mahan, J.D.; Zibners, L.; Naumovski, Z. A Prospective Comparison of Bone Density in Adolescent Girls Receiving Depot Medroxyprogesterone Acetate (Depo-Provera), Levonorgestrel (Norplant), or Oral Contraceptives. J. Pediatrics 1996, 129, 671–676. [Google Scholar] [CrossRef]
- Scholes, D. Bone Mineral Density in Women Using Depot Medroxyprogesterone Acetate for Contraception. Obstet. Gynecol. 1999, 93, 233–238. [Google Scholar] [CrossRef]
- Reddy, D.S. Perimenstrual Catamenial Epilepsy. Women’s Health 2007, 3, 195–206. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Quigg, M.; Smithson, S.D.; Fowler, K.M.; Sursal, T.; Herzog, A.G.; On behalf of the NIH Progesterone Trial Study Group. Laterality and Location Influence Catamenial Seizure Expression in Women with Partial Epilepsy. Neurology 2009, 73, 223–227. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reddy, D.S. The Role of Neurosteroids in the Pathophysiology and Treatment of Catamenial Epilepsy. Epilepsy Res. 2009, 85, 1–30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Buterbaugh, G.G. Estradiol Replacement Facilitates the Acquisition of Seizures Kindled from the Anterior Neocortex in Female Rats. Epilepsy Res. 1989, 4, 207–215. [Google Scholar] [CrossRef]
- Reddy, D.S.; Castaneda, D.C.; O’Malley, B.W.; Rogawski, M.A. Anticonvulsant Activity of Progesterone and Neurosteroids in Progesterone Receptor Knockout Mice. J. Pharmacol. Exp. Ther. 2004, 310, 230–239. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Herzog, A.G. Catamenial Epilepsy: Update on Prevalence, Pathophysiology and Treatment from the Findings of the NIH Progesterone Treatment Trial. Seizure 2015, 28, 18–25. [Google Scholar] [CrossRef] [Green Version]
- Feely, M.; Gibson, J. Intermittent Clobazam for Catamenial Epilepsy: Tolerance Avoided. J. Neurol. Neurosurg. Psychiatry 1984, 47, 1279–1282. [Google Scholar] [CrossRef]
- Lim, L.-L.; Foldvary, N.; Mascha, E.; Lee, J. Acetazolamide in Women with Catamenial Epilepsy. Epilepsia 2001, 42, 746–749. [Google Scholar] [CrossRef]
- Herzog, A.G. Intermittent Progesterone Therapy and Frequency of Complex Partial Seizures in Women with Menstrual Disorders. Neurology 1986, 36, 1607. [Google Scholar] [CrossRef]
- Herzog, A.G. Progesterone Therapy in Women with Complex Partial and Secondary Generalized Seizures. Neurology 1995, 45, 1660–1662. [Google Scholar] [CrossRef]
- Herzog, A.G. Progesterone Therapy in Women with Epilepsy: A 3-Year Follow-Up. Neurology 1999, 52, 1917. [Google Scholar] [CrossRef] [PubMed]
- Reddy, D.S.; Rogawski, M.A. Neurosteroid Replacement Therapy for Catamenial Epilepsy. Neurotherapeutics 2009, 6, 392. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alberto, A.V.; D’Egidio, C.; Agostinelli, S.; Verrotti, A.; Pavone, P. Diagnosis and management of catamenial seizures: A review. Int. J. Women’s Health 2012, 4, 535–541. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bauer, J.; Wild, L.; Flügel, D. The Effect of a Synthetic GnRH Analogue on Catamenial Epilepsy: A Study in Ten Patients. J. Neurol. 1992, 239, 284–286. [Google Scholar] [CrossRef]
- Herzog, A.G.; Mandle, H.B.; Cahill, K.E.; Fowler, K.M.; Hauser, W.A. Differential Impact of Contraceptive Methods on Seizures Varies by Antiepileptic Drug Category: Findings of the Epilepsy Birth Control Registry. Epilepsy Behav. 2016, 60, 112–117. [Google Scholar] [CrossRef] [Green Version]
- Quint, E.H. Menstrual and Reproductive Issues in Adolescents with Physical and Developmental Disabilities. Obstet. Gynecol. 2014, 124, 367–375. [Google Scholar] [CrossRef]
- Pennell, P.B.; Newport, D.J.; Stowe, Z.N.; Helmers, S.L.; Montgomery, J.Q.; Henry, T.R. The Impact of Pregnancy and Childbirth on the Metabolism of Lamotrigine. Neurology 2004, 62, 292–295. [Google Scholar] [CrossRef]
- Chen, H.; Yang, K.; Choi, S.; Fischer, J.H.; Jeong, H. Up-Regulation of UDP-Glucuronosyltransferase (UGT) 1A4 by 17beta-Estradiol: A Potential Mechanism of Increased Lamotrigine Elimination in Pregnancy. Drug Metab. Dispos. 2009, 37, 1841–1847. [Google Scholar] [CrossRef] [Green Version]
- Petrenaite, V.; Öhman, I.; Ekström, L.; Sæbye, D.; Hansen, T.F.; Tomson, T.; Sabers, A. UGT Polymorphisms and Lamotrigine Clearance during Pregnancy. Epilepsy Res. 2018, 140, 199–208. [Google Scholar] [CrossRef] [PubMed]
- Polepally, A.R.; Pennell, P.B.; Brundage, R.C.; Stowe, Z.N.; Newport, D.J.; Viguera, A.C.; Ritchie, J.C.; Birnbaum, A.K. Model-Based Lamotrigine Clearance Changes during Pregnancy: Clinical Implication. Ann. Clin. Transl. Neurol. 2014, 1, 99–106. [Google Scholar] [CrossRef] [PubMed]
- Zhou, J.; Argikar, U.A.; Remmel, R.P. Functional Analysis of UGT1A4(P24T) and UGT1A4(L48V) Variant Enzymes. Pharmacogenomics 2011, 12, 1671–1679. [Google Scholar] [CrossRef] [PubMed]
ASMs That Decrease the Effectiveness of Hormonal Contraceptives | ASMs That Do Not Change the Effectiveness of Hormonal Contraceptives |
---|---|
Carbamazepine (Tegretol, Tegretol XR, Carbatrol, Equetri) Phenobarbital Phenytoin (Dilantin) Primidone (Mysoline) Clobazam (Onfi) Felbamate (Felbatol) Eslicarbazepine (Aptiom) Lamotrigine (Lamictal) 1 Oxcarbazepine (Trileptal) Preampanel 2 Rufinamide (Banzel) Topiramate (Topamax) 3 | Acetazolamide (Diamox) Clonazepam (Klonopin) Diazepam (Valium) Valproic Acid (depakote, Depakene) Ethosuximide (Zarontin) Gabapentin (Neurotin, Graslise, Horizant) Lacosamide (Vimpat) Levetiracetam (Keppra) Lorazepam (Ativan) Pregabalin (Lyrica) Tigabine (Gabitril) Vigabatrin (Sabril) Zonisamide (Zonegran) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Parekh, K.; Kravets, H.D.; Spiegel, R. Special Considerations in the Management of Women with Epilepsy in Reproductive Years. J. Pers. Med. 2022, 12, 88. https://doi.org/10.3390/jpm12010088
Parekh K, Kravets HD, Spiegel R. Special Considerations in the Management of Women with Epilepsy in Reproductive Years. Journal of Personalized Medicine. 2022; 12(1):88. https://doi.org/10.3390/jpm12010088
Chicago/Turabian StyleParekh, Krishna, Hannah Debra Kravets, and Rebecca Spiegel. 2022. "Special Considerations in the Management of Women with Epilepsy in Reproductive Years" Journal of Personalized Medicine 12, no. 1: 88. https://doi.org/10.3390/jpm12010088
APA StyleParekh, K., Kravets, H. D., & Spiegel, R. (2022). Special Considerations in the Management of Women with Epilepsy in Reproductive Years. Journal of Personalized Medicine, 12(1), 88. https://doi.org/10.3390/jpm12010088